Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 14;116(6):731-741.
doi: 10.1038/bjc.2017.22. Epub 2017 Feb 7.

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

David T Arnold  1 , Duneesha De Fonseka  1 , Fergus W Hamilton  2 , Najib M Rahman  3 , Nick A Maskell  1
Affiliations

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

David T Arnold et al. Br J Cancer. .

Abstract

Background: Radiological markers of treatment response and prognostication in malignant pleural mesothelioma have limitations due to the morphology of the disease. Serum or pleural fluid biomarkers that could act as an adjunct to radiological assessment would be of significant value. The aim of this review was to collate and summarise the literature relating to this topic.

Methods: A systematic review was performed on the databases Pubmed and EMBASE to identify relevant studies. Two independent researchers read the abstracts and used the Quality in Prognostic Studies tool to assess the quality of the evidence.

Results: Forty-five studies were identified from the current literature. Twenty studies investigated the role of serum soluble mesothelin with majority suggesting that it has variable utility as a baseline test but when measured serially correlates with treatment response and prognosis. Several studies demonstrated that serum osteopontin correlated with survival at baseline. Other biomarkers have shown prognostic utility in individual studies but are yet to be reproduced in large cohort studies.

Conclusions: From the available literature no serum or pleural fluid biomarker was identified that could be recommended currently for routine clinical practice. However, a falling serum soluble mesothelin might correlate with treatment response and improved survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
See this image and copyright information in PMC

References

    1. Abakay O, Tanrikulu AC, Palanci Y, Abakay A (2014) The value of inflammatory parameters in the prognosis of malignant mesothelioma. J Int Med Res 42(2): 554–565. - PubMed
    1. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323(7306): 224–228. - PMC - PubMed
    1. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF (2009) New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 55(5): 895–903. - PubMed
    1. Armato SG 3rd, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H (2006) Variability in mesothelioma tumor response classification. AJR Am J Roentgenol 186(4): 1000–1006. - PubMed
    1. Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Rahman NM, De Winton E, Clive A, Masani V, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA (2015) The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. Br J Cancer 112(7): 1183–1189. - PMC - PubMed

Publication types

Substances